LPS treatment activates the TLR4/NFκB signaling pathway, leading to the upregulation of pro-inflammatory genes such as IL-6 and VCAM-1, which are key mediators of vascular inflammation and endothelial dysfunction commonly associated with obesity and cardiovascular disease [30]. The gene discussed is VCAM1; the disease is endothelial dysfunction.